AngioDynamics (ANGO) SVP Warren Nighan Jr. sells 23,370 shares at $14.72

Rhea-AI Filing Summary

AngioDynamics Inc. executive Warren Nighan Jr., SVP Quality and Regulatory, reported the sale of 23,370 shares of common stock on 2026-07-30. The reported price of $14.72 per share is a weighted average from multiple trades between $14.65 and $14.80. After this transaction, he directly holds 64,745 shares. The filing indicates the sale was not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 23,370 shares

Net Sell 1 txn

Insider Nighan Warren JR

Role SVP Quality and Regulatory

Sold 23,370 shs ($344K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	23,370	$14.72	$344K

Holdings After Transaction: Common Stock — 64,745 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $14.80, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

Key Figures

Shares sold: 23,370 shares Weighted average sale price: $14.72 per share Trade price range: $14.65–$14.80 per share +1 more

4 metrics

Shares sold 23,370 shares Common Stock sold by Warren Nighan Jr. on 2026-07-30

Weighted average sale price $14.72 per share Weighted average price across multiple trades on 2026-07-30

Trade price range $14.65–$14.80 per share Prices of individual trades underlying the weighted average

Shares owned after transaction 64,745 shares Direct holdings of Warren Nighan Jr. following the sale

Key Terms

weighted average price, Rule 10b5-1, Common Stock, open market or private transaction

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox is not marked as affirming a plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Common Stock financial

"The reported transaction involves Common Stock of AngioDynamics Inc."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"transaction code “S” denotes a sale in open market or private transaction."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 04:45 PM Accepted by SEC EDGAR 07/31/2026 - 04:45 PM Learn about SEC filing dates

FAQ

What insider transaction did ANGO report for Warren Nighan Jr.?

AngioDynamics (ANGO) reported that SVP Quality and Regulatory Warren Nighan Jr. sold 23,370 shares of common stock on 2026-07-30. The sale was reported at a weighted average price of $14.72 per share across multiple trades within a specified price range.

At what prices were Warren Nighan Jr.’s ANGO shares traded?

The reported sale price of $14.72 per share is a weighted average. According to the footnote, the underlying trades occurred at prices ranging from $14.65 to $14.80 per share, inclusive, across multiple separate transactions executed that day.

How many ANGO shares does Warren Nighan Jr. hold after this sale?

Following the reported sale, Warren Nighan Jr. directly holds 64,745 shares of AngioDynamics common stock. This figure reflects his direct ownership position immediately after disposing of 23,370 shares in the transaction disclosed for 2026-07-30.

Was the ANGO insider sale by Warren Nighan Jr. under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, indicating this reported sale was not made pursuant to a Rule 10b5-1 trading plan. No separate footnote describes the transaction as plan-based or pre-arranged.

What type of security did Warren Nighan Jr. sell in the ANGO Form 4?

The reported transaction involves Common Stock of AngioDynamics Inc. Warren Nighan Jr. disposed of 23,370 common shares in an open market or private transaction, as indicated by transaction code “S”, which denotes a sale of non-derivative securities.

How large was Warren Nighan Jr.’s ANGO transaction in share terms?

Warren Nighan Jr. sold 23,370 shares of AngioDynamics common stock. After this transaction, his direct holdings stand at 64,745 shares. The filing does not provide total shares outstanding, so the proportion of the company this represents is not stated.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nighan Warren JR

(Last) (First) (Middle)

ANGIODYNAMICS, INC.

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Quality and Regulatory

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2026		S		23,370	D	$14.72(1)	64,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $14.80, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)